Cargando…

Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame Imatinib-resistance in CML CD34(+) cells

BACKGROUND: The most significant cause of treatment failure in chronic myeloid leukemia (CML) is a persistent population of minimal residual cells. Emerging evidences showed that methylation of SHP-1 contributed to Imatinib (IM) resistance. Baicalein was reported to have an effect on reversal of che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xuefen, Ji, Shufan, Chen, Yuan, Xia, Siwei, Li, Yang, Chen, Li, Li, Yujia, Zhang, Feng, Zhang, Zili, Zheng, Shizhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985268/ https://www.ncbi.nlm.nih.gov/pubmed/36869331 http://dx.doi.org/10.1186/s12964-023-01049-9

Ejemplares similares

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Zinc-induced Dnmt1 expression involves antagonism between MTF-1 and nuclear receptor SHP
por: Zhang, Yuxia, et al.
Publicado: (2012)

BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin
por: Xu, Xuefen, et al.
Publicado: (2016)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

Children’s motivation overcame parental hesitation: active school transportation in Sweden
por: Rutberg, Stina, et al.
Publicado: (2019)

Black Raspberry-Derived Anthocyanins Demethylate Tumor Suppressor Genes Through the Inhibition of DNMT1 and DNMT3B in Colon Cancer Cells
por: Wang, Li-Shu, et al.
Publicado: (2013)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells
por: Zeng, Chengwu, et al.
Publicado: (2018)

Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells
por: Seo, Jung Seon, et al.
Publicado: (2017)

Mobility Repertoires: How Chinese Overseas Students Overcame Pandemic-Induced Immobility
por: Liu, Jiaqi M., et al.
Publicado: (2023)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells
por: Azevedo Portilho, Nathalia, et al.
Publicado: (2021)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors
por: Laranjeira, Angelo B. A., et al.
Publicado: (2023)

The Robot-Assisted Extravesical Anti-reflux Surgery: How We Overcame the Learning Curve
por: Sahadev, Ravindra, et al.
Publicado: (2019)

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
por: Aceves-Luquero, Clara I., et al.
Publicado: (2009)

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2011)

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target
por: Toman, O., et al.
Publicado: (2016)

6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells
por: Flesner, Brian K, et al.
Publicado: (2014)

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML
por: Liu, Yanjun, et al.
Publicado: (2021)

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib
por: Jin, Yanli, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

How one institution overcame the challenges to start an MRI-based brachytherapy program for cervical cancer
por: Harkenrider, Matthew M., et al.
Publicado: (2017)

Host DNA Demethylation Induced by DNMT1 Inhibition Up-Regulates Antiviral OASL Protein during Influenza a Virus Infection
por: Zhao, Zhiyan, et al.
Publicado: (2023)

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
por: Wang, Li, et al.
Publicado: (2022)

Hemi-methylated CpG sites connect Dnmt1-knockdown-induced and Tet1-induced DNA demethylation during somatic cell reprogramming
por: He, Songwei, et al.
Publicado: (2019)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
por: Mohajeri, Ehsan, et al.
Publicado: (2015)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Dihydroartemisinin Induces Ferroptosis in HCC by Promoting the Formation of PEBP1/15-LO
por: Su, Ying, et al.
Publicado: (2021)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Reprogrammable CRISPR/dCas9-based recruitment of DNMT1 for site-specific DNA demethylation and gene regulation
por: Lu, Anrui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tg1faq6u15lff36rf9hi231gdp